Argen-X (F:1AE) — Market Cap & Net Worth
Market Cap & Net Worth: Argen-X (1AE)
Argen-X (F:1AE) has a market capitalization of $41.67 Billion (€35.64 Billion) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #660 globally and #139 in its home market, demonstrating a -3.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Argen-X's stock price €856.40 by its total outstanding shares 62187771 (62.19 Million). Also see Argen-X balance sheet assets for a full breakdown of the balance sheet.
Argen-X Market Cap History: 2018 to 2026
Argen-X's market capitalization history from 2018 to 2026. Data shows growth from $6.01 Billion to $62.26 Billion (35.70% CAGR). Also see 1AE cash flow metrics for how efficiently the company converts equity into cash flow.
Argen-X Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Argen-X's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 1AE stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
12.45x
Argen-X's market cap is 12.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
40.03x
Argen-X's market cap is 40.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $6.01 Billion | $21.48 Million | -$66.64 Million | 279.89x | N/A |
| 2019 | $10.48 Billion | $69.78 Million | -$162.97 Million | 150.13x | N/A |
| 2020 | $17.54 Billion | $36.42 Million | -$528.92 Million | 481.43x | N/A |
| 2021 | $22.45 Billion | $497.28 Million | -$408.26 Million | 45.15x | N/A |
| 2022 | $25.50 Billion | $410.75 Million | -$709.59 Million | 62.08x | N/A |
| 2023 | $25.05 Billion | $1.23 Billion | -$295.05 Million | 20.43x | N/A |
| 2024 | $43.68 Billion | $2.19 Billion | $833.04 Million | 19.94x | 52.44x |
| 2025 | $51.72 Billion | $4.15 Billion | $1.29 Billion | 12.45x | 40.03x |
Competitor Companies of 1AE by Market Capitalization
Companies near Argen-X in the global market cap rankings as of September 19, 2026. Review Argen-X (1AE) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Argen-X by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Argen-X Historical Marketcap From 2018 to 2026
Between 2018 and today, Argen-X's market cap moved from $6.01 Billion to $ 62.26 Billion, with a yearly change of 35.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €62.26 Billion | +20.38% |
| 2025 | €51.72 Billion | +18.41% |
| 2024 | €43.68 Billion | +74.35% |
| 2023 | €25.05 Billion | -1.74% |
| 2022 | €25.50 Billion | +13.57% |
| 2021 | €22.45 Billion | +28.03% |
| 2020 | €17.54 Billion | +67.38% |
| 2019 | €10.48 Billion | +74.24% |
| 2018 | €6.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Argen-X was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.67 Billion USD |
| MoneyControl | $41.67 Billion USD |
| MarketWatch | $41.67 Billion USD |
| marketcap.company | $41.67 Billion USD |
| Reuters | $41.67 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more